Skip to content

ComPro Pharma: sector benchmark

Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.

Sector benchmark

ComPro Pharma

BE 0746.429.351
NACE 72.101, Research and development on biotechnology
NACE division 72, Scientific research and development all sizesfiscal years 2021 to 202599 to 912 sector peers per ratio

Summary

fiscal year 2025

ComPro Pharma does better than half of its sector on 5 of the 10 ratios compared.

most favourable quarter above the median below the median least favourable quarter
Strongest points
  • Return on equitybetter than 95%
  • Return on assetsbetter than 95%
  • Interest coveragebetter than 89%
Points to watch
  • Debt to equitybetter than 8%
  • Working-capital ratiobetter than 10%
  • Current ratiobetter than 14%

Solvency and debt

How soundly the company is financed.
Solvency
11.9%▼2025

Solvency is below 80% of 912 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025
Debt to equity
7.38▲2025

Debt to equity is above 92% of 902 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025
Interest coverage
373.75▲2025

Interest coverage is above 89% of 805 sector peers: in the most favourable quarter.

20212022202320242025

Liquidity

Whether it can pay its short-term bills.
Current ratio
0.69▼2025

The current ratio is below 86% of 889 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025
Working-capital ratio
-27.0%▼2025

The working-capital ratio is below 90% of 911 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025

Profitability

What the company earns on its assets and its sales.
Return on equity
592.1%▲2025

Return on equity is above 95% of 773 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Return on assets
70.6%▲2025

Return on assets is above 95% of 910 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Net margin
34.9%▲2023

The net margin is above 88% of 115 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Gross margin
41.6%▲2023

The gross margin is below 62% of 99 sector peers: less favourable than the median.

Position against the sector stable since 2021.

20212022202320242025

Working-capital cycle

How long cash is tied up in customers, suppliers and stock.
Days sales outstanding
36days▲2023

Days sales outstanding is below 85% of 116 sector peers: in the most favourable quarter.

Position against the sector stable since 2021.

20212022202320242025
Days payable outstanding
1days▼2023

Days payable outstanding is below 95% of 117 sector peers.

20212022202320242025

Not computable

Long-term debt ratio, EBITDA margin, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.

Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 29 September 2026 via checked.be.